$CRVO

H.C. Wainwright reiterated a Buy rating on CervoMed (NASDAQ:CRVO) with a $25 price target after the company presented Phase 2a trial data showing a reduction in a biomarker of neuronal damage. The stock trades at $2.24, near its 52-week low. Canaccord Genuity lowered its target to $18, citing funding uncertainty.

CervoMed Inc. (CRVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026 On average, reduction in plasma neu

CervoMed Inc. (CRVO) reported a 3.1 pg/mL reduction in plasma NfL levels in a 12-week Phase 2a trial of neflamapimod for nfvPPA, a form of frontotemporal dementia. The study involved 25 participants, with 18 having elevated baseline NfL levels. The company plans to present 24-week data in November 2026 and topline clinical data in Q1 2027. No treatments are currently approved for nfvPPA in the U.S. or EU.

CervoMed published an investor presentation on its website under Regulation FD, covering business, clinical studies, development plans, and financial position. The presentation is for use in investor and analyst meetings and may be updated periodically. The information is not deemed filed for SEC liability purposes.

H.C. Wainwright reiterated a Buy rating and $25 price target on CervoMed (CRVO) following advances in its neflamapimod drug program. The stock trades at $3.02 with a $45.66M market cap, up 13% in the past week. The company announced a new 50mg tablet formulation for twice-daily dosing, FDA approval for higher doses, and controlled manufacturing processes. Analysts' price targets range from $7 to $25.

CervoMed Inc. (CRVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA

CervoMed (CRVO) announced a new 50 mg tablet formulation for neflamapimod, meeting Phase 1 study objectives. The FDA removed a plasma drug exposure limit. The company plans a 100 mg twice-daily regimen for future trials, aiming to increase trough concentrations. CRVO stock closed at $2.54, up 0.79%.

CervoMed Inc. (CRVO) announced that initial results from its Phase 2a trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA) will be presented at the ISFTD Annual Meeting. The trial, involving 25 participants, aims to evaluate the safety and efficacy of neflamapimod, a drug targeting neuroinflammation and synaptic dysfunction. NfvPPA, a type of frontotemporal dementia, currently has no approved treatments in the U.S. or E.U.

CervoMed Inc. (CRVO) announced that its drug candidate, neflamapimod, received an Innovation Passport from the UK's ILAP for treating Dementia with Lewy Bodies (DLB). This designation accelerates regulatory review and market access in the UK, validating the drug's potential. The company is seeking a partner for Phase 3 trials and expects interim data from other trials in late 2026.

CervoMed Inc. (CRVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation und